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Based on the high durable complete response propor-
tion seen in the earlier study [1], we continue to study the
TICE regimen, with carboplatin dose calculated by the Cal-
vert formula using the Jelliffe formula to estimate GFR. In
total, nearly 90 patients have been treated with the TICE
regimen in one or the other study at our center. Neuro-otic
toxicity is observed [1], but to a lesser degree than that
observed in the nine patients reported by Dubs et al. Also,
we avoid exposure to other neuro-otic toxic drugs, most
notably aminoglycoside antibiotics during periods of nadir
fever whenever possible.
The letter by Dubs et al highlights the need to continue
clinical investigations in patients treated with high-dose
carboplatin regimens for refractory germ cell tumors—to
find the most effective and tolerable regimen and optimal
dosing method for carboplatin. In this regard, improving
efficacy is the primary objective, since the high-dose che-
motherapy is potentially curative.
Robert J. Motzer
Memorial Sloan-Kettering Cancer Center, New York, NY
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High-Risk Lesions in High-Risk
Women: A High-Risk Formalin-
Based Biology!
TO THE EDITOR: We have reviewed three recent indepen-
dent series reporting on benign breast disease and preinva-
sive lesions in prophylactic mastectomies from high-risk
women (Table 1). Hypothesis regarding specific breast can-
cer progression in BRCA mutation carriers is portrayed.
Benign breast disease is of major interest in breast
pathology. Many terms are used to refer to it: premalignant
lesions, precursor lesions, risk marker lesions. It is still a
matter of debate among pathologists and basic science re-
searchers whether such lesions are directly connected to the
subsequent invasive cancers seen in a patient. Actually,
patients with such high-risk lesions are at higher risk for
developing invasive breast cancer. On another hand, high-
risk women are defined by the presence of a major familial
cancer history, suggesting the transmission of germline mu-
tations including breast cancer susceptibility genes, such as
BRCA1 and BRCA2, or other yet unknown genes. Women
with such genetic predisposition, particularly BRCA muta-
tion carriers, are at high risk for developing invasive breast
cancers. Three recent series have tried to assess this high-
risk relation between somatic breast lesions and germline
mutations. Are high-risk lesions more prevalent in BRCA
mutation carriers, therefore explaining the higher risk ob-
served in those patients? Or should this higher risk be ex-
plained by other, yet unrecognized biomarkers specific to
BRCA mutation carriers? Three pathology-based series




BRCA mutation carriers, n 44 24 39
Personal breast cancer history in
BRCA mutation carriers, n
11 (42% of 26, data extracted) 17 28
Controls, n No control group presented 48 74
Controls definition Data for 23 high-risk patients
with no BRCA mutations
could be extracted from
Table 1
Selected autopsy cases as non-
hispanic white women with
no personal history of breast
cancer
Without a known family history of
breast carcinoma
Pathology review No details One pathologist Two pathologists, blind for status
Sampling, slides per case v
control
19 (mean number for all
subjects)
14.1 v 9.2 7.2 v 8.1†
Hyperplasia with no atypia, cases
v controls
Not evaluated Not evaluated 5% v 26%
ADH, BRCA v sporadic Grouped under high risk 38% v 4% 4% v 2%†
ALH, BRCA v sporadic lesions 43% v 83% (BRCA 13% v 0% Grouped under lobular neoplasia
LCIS, BRCA v sporadic v non-BRCA, data extracted) 4% v 2%† 0% v 5%†
DCIS, BRCA v sporadic 13% v 0% 0% v 0%
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have recently tried to answer this question by evaluating the
prevalence of high-risk lesions in BRCA patients who un-
derwent unilateral prophylactic mastectomy (PM) when
personal history of breast cancer was present, or bilateral
PM when there was not yet any known personal breast
cancer history. Among high-risk lesions, ductal carcinoma-
in-situ (DCIS) confers an 8- to 10-fold increase in relative
risk for a given patient. First pathology reports on therapeu-
tic mastectomies have shown a lower prevalence of DCIS
component associated with invasive cancers in BRCA muta-
tion carriers, suggesting that BRCA cancers arose de novo from
breast epithelium without a preinvasive component [1,2]. In
addition, epidemiologic studies suggested lower prevalence of
BRCA mutations in patients with DCIS [3]. The more recent
series based on prophylactic mastectomies, reporting on pre-
invasive disease, are of interest since all three agreed on the
specific cancer progression in BRCA mutation carriers.
The study from the Nijmegen University (Nijmegen,
the Netherlands) [4] selected 67 patients at high hereditary
risk, from whom 44 had a BRCA mutation (38 BRCA1 and
six BRCA2), who underwent unilateral (26 patients) and
bilateral (41 patients) PM. Fifty-seven (57%) patients pre-
sented one or more high-risk lesions, comprising lesions
such as atypical ductal hyperplasia, atypical lobular hyper-
plasia, lobular carcinoma-in-situ, and DCIS. High-risk le-
sions were encountered in older patients, who were less
likely to have had a previous oophorectomy and had less
chance of being a BRCA mutation carrier. Nineteen (43%)
BRCA mutation carriers had high-risk lesions, from whom
13 had unilateral PM and six had bilateral PM (data ex-
tracted). Among BRCA mutation carriers with high-risk
lesions, 20% had previous oophorectomy compared to 42%
who did not, stressing the hormonal dependence between
ovaries and breast parenchyma. The grouping of such different
lesions in the high-risk category is somehow questionable,
since the clinical management, the pathology and biology of
atypical ductal hyperplasia, lobular neoplasia (atypical lobular
hyperplasia and lobular carcinoma-in-situ), and DCIS are ex-
tremely different. DCIS was seen on prophylactic mastecto-
mies in 9% of BRCA mutation carriers, and in 26% of patients
with no mutations (data extracted). Of note is that neither
clinical exams, nor imaging studies including magnetic reso-
nance imaging, were able to detect DCIS. Therefore, prophy-
lactic surgery offered to BRCA patients might be more efficient
than surveillance, as suggested by another study [5]. The
Dutch authors observed that the occurrence of these high-risk
lesions is higher than what was reported in the literature, and
explained it by their extensive sampling of breast specimens. As
they pointed out, a major limitation of their study is the ab-
sence of a control group, which is an essential condition for
studying the pathophysiology of the cancer progression in
BRCA mutation carriers.
The study [6] from the Memorial Sloan-Kettering Can-
cer Center (New York, NY) examined breast materials from
24 BRCA mutation carriers who underwent prophylactic
mastectomies (71% had previous breast cancer) at their
institution between 1987 and 2001, and from 48 controls
(with no personal history of breast cancer) extracted from
an autopsy registry (performed between 1978 and 1983).
There was higher incidence of almost all labeled benign
breast lesions (most of which could be grouped under the
nonproliferative fibrocystic changes spectrum) in BRCA
mutation carriers compared to the autopsy cases. High-risk
ductal and high-risk lobular lesions were more frequently
encountered in breast tissue from BRCA patients. Thirteen
percent of those patients had DCIS compared to none of the
controls. The findings of lower prevalence of high-risk le-
sions in the autopsy group could result from different con-
founding biases. There were significant differences in the
number of slides per breast (14 slides for BRCA mutation
carriers versus nine slides for controls), specimens han-
dling, surgical (in a hereditary setting, someone would be
very careful in grossing breast tissue) versus autopsy proce-
dures (where sampling is less directed). Also, the groups’ epi-
demiologic characteristics differed in their ethnic background
and personal breast cancer history (the control cases could all
be considered as having had bilateral PM).
The report from the Mayo Clinic explored two groups;
one underwent unilateral PM after a therapeutic mastec-
tomy for breast cancer, while the second one underwent
bilateral PM [7]. Overall, there were 180 high-risk patients,
including 39 BRCA mutation carriers and 325 sporadic
controls, who were matched by age at diagnosis and date of
surgery. There was no difference in slides number between
cases and controls. They observed lower prevalence of pro-
liferative fibrocystic changes (moderate and florid hyper-
plasia with no atypia) in BRCA mutation carriers compared
to the remaining hereditary and sporadic patients. The
same trend was observed in prophylactic mastectomies
from BRCA patients with or without a personal history of
breast cancer, as well as in patients with BRCA1 mutations
or BRCA2 mutations compared to their respective controls.
Reporting their findings from therapeutic mastectomies,
authors from the Mayo Clinic (Rochester, MN) have con-
firmed earlier data regarding the higher grade of invasive
cancers in BRCA mutation carriers; nevertheless, they re-
ported similar prevalence of DCIS among BRCA cancers
and remaining cancers, emphasizing the presence of an in
situ component in BRCA carcinogenesis.
Although slight differences are seen among those three
reports, especially in the materials sections and in the ways
cases and controls were matched, they present converging
data. BRCA cancer progression goes through morphologi-
cally recognizable steps, hyperplasia, and in situ cancer.
As surgical pathology is an instant formalin-fixed par-
affin-embedded picture of cancer progression, the presence
of a lower prevalence of high-risk lesions may be explained
by an accelerated tumorigenesis, and a quick transition of a
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clone into putative intermediate steps to invasive disease
rather than the de novo occurrence of invasive cancer (Fig
1). The high-grade and highly proliferative invasive breast
cancers seen in BRCA mutation carriers militate for this
hypothesis of a quick passage of a tumor clone through
cancer progression steps [2]. Although the biology and the
pathology of breast cancers related to BRCA1 or BRCA2
mutations show various differences, all three reports have
brought together data from BRCA1 and BRCA2 related
breast parenchyma. This was probably done because of
sample size issues. Starting from these first data, we
believe that it is the time for large collaborative multi-
institutional studies exploring benign breast disease in
hereditary patients. The latter ones, at higher risk for
developing invasive cancers, should benefit from an
adapted and adjusted clinical and radiologic surveillance
in order to detect early lesions and first events. Experimental
pathology could help in identifying molecular biomarkers
stratifying patients with high-risk lesions identified by the
means of surgical pathology in two groups, some to be closely
followed at major risk for subsequent invasive cancer, and
others that are at lower risk for it. Prophylactic surgery might
be, in some settings, a reasonable option to be proposed to
those high-risk patients with high-risk lesions until more clin-
ical trials and molecular data would show other procedures to
be more beneficial.
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IN REPLY: Adem et al review three studies on breast
pathology in patients with hereditary breast cancer. They con-
clude that the available data support their previous claim that
breast cancer progression from benign breast disease to inva-
sive cancer is more rapid in BRCA mutation carriers [1]. They
list the following arguments: 1) A low prevalence (2-2.5%) of
high-risk lesions in prophylactically removed breasts from
BRCA-mutation carriers, and 2) a high incidence of cancer in
BRCA-mutation carriers. This model may be true. On the
other hand, our study [2] and the Memorial Sloan-Kettering
Cancer Center study [3] found a much higher prevalence of
high-risk lesions (43% and 46%, respectively). Both these
studies used more extensive breast tissue sampling protocols
and therefore achieved higher sensitivity. Thus, the hypothesis
that BRCA mutation carriers have a higher prevalence of high-
risk lesions cannot be discarded. In fact, our data and that from
the Memorial Sloan-Kettering Cancer Center study seem to
favor increased incidence of lesions over rapid progression
[2,3]. We agree that future studies are required to resolve
whether progression or incidence of high-risk lesions is more
important or whether other factors are involved. We note that
irrespective of the underlying biologic model, the data argue
Fig 1. Cancer progression in BRCA is faster than in sporadic patients,
emphasizing the lower prevalence of precursor lesions in the former ones
compared to the latter ones. As the state to rate function is higher in BRCA
mutation carriers, there are fewer encounters (mutation carriers) in the
putative precursor lesions compared to sporadic patients. IDC, invasive
ductal carcinoma; DCIS, ductal carcinoma in situ; Atypia, atypical ductal
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